Dr. Stephanie B. Seminara
Biography & Research Background
Stephanie B. Seminara, MD, is affiliated with the Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School. Dr. Seminara led one of the independent groups that discovered loss-of-function mutations in KISS1R (GPR54) cause idiopathic hypogonadotropic hypogonadism and pubertal failure (NEJM, 2003), establishing kisspeptin as the gatekeeper of sexual maturation. Her subsequent work characterized kisspeptin-induced desensitization of GPR54 in primate models, demonstrating the mechanism underlying tachyphylaxis with continuous exposure. Stephanie B. Seminara is being referenced as one of the leading scientists involved in the research and development of Kisspeptin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Stephanie B. Seminara is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Stephanie B. Seminara is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.